Economic evaluation of the effect of needle and syringe programs on skin, soft tissue, and vascular infections in people who inject drugs: a microsimulation modelling approach.
Humans
Substance Abuse, Intravenous
/ complications
Needle-Exchange Programs
/ economics
Cost-Benefit Analysis
Soft Tissue Infections
Quality-Adjusted Life Years
Vascular Diseases
/ economics
Skin Diseases, Infectious
/ prevention & control
Canada
/ epidemiology
Computer Simulation
Harm Reduction
Female
Male
Adult
Models, Economic
Economic modelling
Microsimulation
Needle and syringe program
Recurrent-event survival analysis
Skin, Soft tissue and vascular infections
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
28 Jun 2024
28 Jun 2024
Historique:
received:
12
03
2024
accepted:
14
06
2024
medline:
29
6
2024
pubmed:
29
6
2024
entrez:
29
6
2024
Statut:
epublish
Résumé
Needle and syringe programs (NSP) are effective harm-reduction strategies against HIV and hepatitis C. Although skin, soft tissue, and vascular infections (SSTVI) are the most common morbidities in people who inject drugs (PWID), the extent to which NSP are clinically and cost-effective in relation to SSTVI in PWID remains unclear. The objective of this study was to model the clinical- and cost-effectiveness of NSP with respect to treatment of SSTVI in PWID. We performed a model-based, economic evaluation comparing a scenario with NSP to a scenario without NSP. We developed a microsimulation model to generate two cohorts of 100,000 individuals corresponding to each NSP scenario and estimated quality-adjusted life-years (QALY) and cost (in 2022 Canadian dollars) over a 5-year time horizon (1.5% per annum for costs and outcomes). To assess the clinical effectiveness of NSP, we conducted survival analysis that accounted for the recurrent use of health care services for treating SSTVI and SSTVI mortality in the presence of competing risks. The incremental cost-effectiveness ratio associated with NSP was $70,278 per QALY, with incremental cost and QALY gains corresponding to $1207 and 0.017 QALY, respectively. Under the scenario with NSP, there were 788 fewer SSTVI deaths per 100,000 PWID, corresponding to 24% lower relative hazard of mortality from SSTVI (hazard ratio [HR] = 0.76; 95% confidence interval [CI] = 0.72-0.80). Health service utilization over the 5-year period remained lower under the scenario with NSP (outpatient: 66,511 vs. 86,879; emergency department: 9920 vs. 12,922; inpatient: 4282 vs. 5596). Relatedly, having NSP was associated with a modest reduction in the relative hazard of recurrent outpatient visits (HR = 0.96; 95% CI = 0.95-0.97) for purulent SSTVI as well as outpatient (HR = 0.88; 95% CI = 0.87-0.88) and emergency department visits (HR = 0.98; 95% CI = 0.97-0.99) for non-purulent SSTVI. Both the individuals and the healthcare system benefit from NSP through lower risk of SSTVI mortality and prevention of recurrent outpatient and emergency department visits to treat SSTVI. The microsimulation framework provides insights into clinical and economic implications of NSP, which can serve as valuable evidence that can aid decision-making in expansion of NSP services.
Sections du résumé
BACKGROUND
BACKGROUND
Needle and syringe programs (NSP) are effective harm-reduction strategies against HIV and hepatitis C. Although skin, soft tissue, and vascular infections (SSTVI) are the most common morbidities in people who inject drugs (PWID), the extent to which NSP are clinically and cost-effective in relation to SSTVI in PWID remains unclear. The objective of this study was to model the clinical- and cost-effectiveness of NSP with respect to treatment of SSTVI in PWID.
METHODS
METHODS
We performed a model-based, economic evaluation comparing a scenario with NSP to a scenario without NSP. We developed a microsimulation model to generate two cohorts of 100,000 individuals corresponding to each NSP scenario and estimated quality-adjusted life-years (QALY) and cost (in 2022 Canadian dollars) over a 5-year time horizon (1.5% per annum for costs and outcomes). To assess the clinical effectiveness of NSP, we conducted survival analysis that accounted for the recurrent use of health care services for treating SSTVI and SSTVI mortality in the presence of competing risks.
RESULTS
RESULTS
The incremental cost-effectiveness ratio associated with NSP was $70,278 per QALY, with incremental cost and QALY gains corresponding to $1207 and 0.017 QALY, respectively. Under the scenario with NSP, there were 788 fewer SSTVI deaths per 100,000 PWID, corresponding to 24% lower relative hazard of mortality from SSTVI (hazard ratio [HR] = 0.76; 95% confidence interval [CI] = 0.72-0.80). Health service utilization over the 5-year period remained lower under the scenario with NSP (outpatient: 66,511 vs. 86,879; emergency department: 9920 vs. 12,922; inpatient: 4282 vs. 5596). Relatedly, having NSP was associated with a modest reduction in the relative hazard of recurrent outpatient visits (HR = 0.96; 95% CI = 0.95-0.97) for purulent SSTVI as well as outpatient (HR = 0.88; 95% CI = 0.87-0.88) and emergency department visits (HR = 0.98; 95% CI = 0.97-0.99) for non-purulent SSTVI.
CONCLUSIONS
CONCLUSIONS
Both the individuals and the healthcare system benefit from NSP through lower risk of SSTVI mortality and prevention of recurrent outpatient and emergency department visits to treat SSTVI. The microsimulation framework provides insights into clinical and economic implications of NSP, which can serve as valuable evidence that can aid decision-making in expansion of NSP services.
Identifiants
pubmed: 38943164
doi: 10.1186/s12954-024-01037-3
pii: 10.1186/s12954-024-01037-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
126Subventions
Organisme : CIHR
ID : 436351
Pays : Canada
Organisme : CIHR
ID : 436351
Pays : Canada
Informations de copyright
© 2024. The Author(s).
Références
Mathers BM, et al. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(2):102–23.
pubmed: 23554523
pmcid: 3605003
doi: 10.2471/BLT.12.108282
Mathers BM, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45.
pubmed: 18817968
doi: 10.1016/S0140-6736(08)61311-2
Trickey A, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4(6):435–44.
pubmed: 30981685
pmcid: 6698583
doi: 10.1016/S2468-1253(19)30085-8
Degenhardt L, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–207.
pubmed: 29074409
pmcid: 5683738
doi: 10.1016/S2214-109X(17)30375-3
Tookes H, et al. A cost analysis of hospitalizations for infections related to injection drug use at a County Safety-Net Hospital in Miami, Florida. PLoS ONE. 2015;10(6):e0129360.
pubmed: 26075888
pmcid: 4468183
doi: 10.1371/journal.pone.0129360
Kendall CE, et al. A cohort study examining emergency department visits and hospital admissions among people who use drugs in Ottawa, Canada. Harm Reduct J. 2017;14(1):16.
pubmed: 28494791
pmcid: 5427560
doi: 10.1186/s12954-017-0143-4
Marks M, et al. Needles and the damage done: reasons for admission and financial costs associated with injecting drug use in a Central London Teaching Hospital. J Infect. 2013;66(1):95–102.
pubmed: 23068454
doi: 10.1016/j.jinf.2012.10.004
Takahashi TA, et al. Predictors of hospitalization for injection drug users seeking care for soft tissue infections. J Gen Intern Med. 2007;22(3):382–8.
pubmed: 17356973
pmcid: 1824763
doi: 10.1007/s11606-006-0079-y
Lewer D, Harris M, Hope V. Opiate injection-associated skin, soft tissue, and vascular infections, England, UK, 1997–2016. Emerg Infect Dis. 2017;23(8):1400–3.
pubmed: 28726606
pmcid: 5547794
doi: 10.3201/eid2308.170439
Dwyer R, et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug Alcohol Depend. 2009;100(1–2):9–16.
pubmed: 19013725
doi: 10.1016/j.drugalcdep.2008.08.016
Topp L, et al. Prevalence and predictors of injecting-related injury and disease among clients of Australia’s needle and syringe programs. Aust N Z J Public Health. 2008;32(1):34–7.
pubmed: 18290911
doi: 10.1111/j.1753-6405.2008.00163.x
Blome A, et al. Emergency department medication dispensing reduces return visits and admissions. Am J Emerg Med. 2020;38(11):2387–90.
pubmed: 33041118
doi: 10.1016/j.ajem.2020.08.082
Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol. 2008;19(2):173–84.
pubmed: 19352449
pmcid: 2605859
doi: 10.1155/2008/846453
Stevens DL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147–59.
pubmed: 24947530
doi: 10.1093/cid/ciu444
Sartelli M, et al. 2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World J Emerg Surg. 2018;13:58.
pubmed: 30564282
pmcid: 6295010
doi: 10.1186/s13017-018-0219-9
Doran J, et al. Factors associated with skin and soft tissue infections among people who inject drugs in the United Kingdom: a comparative examination of data from two surveys. Drug Alcohol Depend. 2020;213:108080.
pubmed: 32526658
doi: 10.1016/j.drugalcdep.2020.108080
Barocas JA, et al. Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections. Drug Alcohol Depend. 2020;215:108207.
pubmed: 32795883
pmcid: 7502512
doi: 10.1016/j.drugalcdep.2020.108207
Jawa R, et al. Association of skin infections with sharing of injection drug preparation equipment among people who inject drugs. Int J Drug Policy. 2021;94:103198.
pubmed: 33744668
pmcid: 8373634
doi: 10.1016/j.drugpo.2021.103198
Wright T, et al. Prevalence and severity of abscesses and cellulitis, and their associations with other health outcomes, in a community-based study of people who inject drugs in London, UK. PLoS ONE. 2020;15(7):e0235350.
pubmed: 32663203
pmcid: 7360031
doi: 10.1371/journal.pone.0235350
Mosseler K, et al. Epidemiology, microbiology, and clinical outcomes among patients with intravenous drug use-associated infective endocarditis in New Brunswick. CJC Open. 2020;2(5):379–85.
pubmed: 32995724
pmcid: 7499377
doi: 10.1016/j.cjco.2020.05.002
Gomes T, et al. Trends in hospitalizations for serious infections among people with opioid use disorder in Ontario, Canada. J Addict Med. 2022;16(4):433–9.
pubmed: 34711742
doi: 10.1097/ADM.0000000000000928
Kenny KS, et al. Association of illicit fentanyl use with injection risk practices among people who inject drugs. AIDS Behav. 2023;27(6):1757–65.
pubmed: 36401145
doi: 10.1007/s10461-022-03908-x
Scheim AI, et al. The Ontario integrated supervised injection services cohort study of people who inject drugs in Toronto, Canada (OiSIS-Toronto): Cohort Profile. J Urban Health. 2021;98(4):538–50.
pubmed: 34181179
pmcid: 8237772
doi: 10.1007/s11524-021-00547-w
Bouchard M, et al. Estimating the size of the fentanyl market in British Columbia. 2020.
Biancarelli DL, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80–6.
pubmed: 30884432
pmcid: 6521691
doi: 10.1016/j.drugalcdep.2019.01.037
Ozga JE, et al. A community-based study of abscess self-treatment and barriers to medical care among people who inject drugs in the United States. Health Soc Care Community. 2022;30(5):1798–808.
pubmed: 34469034
doi: 10.1111/hsc.13559
Lloyd-Smith E, et al. Determinants of hospitalization for a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health. 2010;10:327.
pubmed: 20534148
pmcid: 2890691
doi: 10.1186/1471-2458-10-327
Hankins CA. Syringe exchange in Canada: good but not enough to stem the HIV tide. Subst Use Misuse. 1998;33(5):1129–46.
pubmed: 9596380
doi: 10.3109/10826089809062211
CACTUS Montreal. Our History. 2023 [cited 2023 October 2, 2023]; Available from: https://cactusmontreal.org/en/all-about-cactus/history/ .
Hankins CA, et al. Le programme d’échange de seringues de CACTUS-Montréal: Description du service et profil comportemental de la clientèle. Revue sexologique. 1993;1:57–75.
Aspinall EJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235–48.
pubmed: 24374889
doi: 10.1093/ije/dyt243
MacNeil J, Pauly B. Needle exchange as a safe haven in an unsafe world. Drug Alcohol Rev. 2011;30(1):26–32.
pubmed: 21219494
doi: 10.1111/j.1465-3362.2010.00188.x
Werb D, et al. Patterns of injection drug use cessation during an expansion of syringe exchange services in a Canadian setting. Drug Alcohol Depend. 2013;132(3):535–40.
pubmed: 23642315
pmcid: 3762907
doi: 10.1016/j.drugalcdep.2013.03.024
Bartholomew TS, et al. Reduction in injection risk behaviors after implementation of a syringe services program, Miami, Florida. J Subst Abuse Treat. 2021;127:108344.
pubmed: 34134863
pmcid: 8221088
doi: 10.1016/j.jsat.2021.108344
Marotta PL, et al. Assessing the relationship between syringe exchange, pharmacy, and street sources of accessing syringes and injection drug use behavior in a pooled nationally representative sample of people who inject drugs in the United States from 2002 to 2019. Harm Reduct J. 2021;18(1):115.
pubmed: 34789270
pmcid: 8600731
doi: 10.1186/s12954-021-00565-6
Fernandes RM, et al. Effectiveness of needle and syringe Programmes in people who inject drugs—an overview of systematic reviews. BMC Public Health. 2017;17(1):309.
pubmed: 28399843
pmcid: 5387338
doi: 10.1186/s12889-017-4210-2
Sanchez DP, et al. Wounds and skin and soft tissue infections in people who inject drugs and the utility of syringe service programs in their management. Adv Wound Care (New Rochelle). 2021;10(10):571–82.
pubmed: 33913781
doi: 10.1089/wound.2020.1243
Thakarar K, et al. Injections and infections: understanding syringe service program utilization in a rural state. Harm Reduct J. 2021;18(1):74.
pubmed: 34273986
pmcid: 8285696
doi: 10.1186/s12954-021-00524-1
Jozaghi E, Reid AA, Andresen MA. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada. Subst Abuse Treat Prev Policy. 2013;8:25.
pubmed: 23837814
pmcid: 3710233
doi: 10.1186/1747-597X-8-25
Enns EA, et al. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada. Addiction. 2016;111(3):475–89.
pubmed: 26616368
doi: 10.1111/add.13195
Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver’s supervised injection facility. CMAJ. 2008;179(11):1143–51.
pubmed: 19015565
pmcid: 2582765
doi: 10.1503/cmaj.080808
Andresen MA, Boyd N. A cost-benefit and cost-effectiveness analysis of Vancouver’s supervised injection facility. Int J Drug Policy. 2010;21(1):70–6.
pubmed: 19423324
doi: 10.1016/j.drugpo.2009.03.004
Adams JW, et al. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction. 2022;117(10):2635–48.
pubmed: 35315148
pmcid: 9951221
doi: 10.1111/add.15883
Caro JJ, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1. Value Health. 2012;15(6):796–803.
pubmed: 22999128
doi: 10.1016/j.jval.2012.06.012
Krijkamp EM, et al. Microsimulation modeling for health decision sciences using R: a tutorial. Med Decis Making. 2018;38(3):400–22.
pubmed: 29587047
pmcid: 6349385
doi: 10.1177/0272989X18754513
Leclerc P, et al. Surveillance des maladies infectieuses chez les personnes qui utilisent des drogues par injection. 2023 [cited 2023 December 28, 2023]; Available from: https://www.inspq.qc.ca/publications/3362 .
Mulliken JS, Doernberg SM. UCSF Medical Center Guideline for the Management of Suspected Skin and Soft Tissue Infections in Adults. 2019 [cited 2023 October 10, 2023]; Available from: https://idmp.ucsf.edu/sites/g/files/tkssra4251/f/UCSF%20SSTI%20Guideline%20FINAL_0.pdf .
Barton M, et al. Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners. Can J Infect Dis Med Microbiol. 2006;17(Suppl C):4C-24C.
pubmed: 23365589
pmcid: 3555463
doi: 10.1155/2006/402361
Institut de la Statistique du Québec. Dictionnaire de données. [cited 2023 December 20, 2023]; Available from: https://statistique.quebec.ca/services-recherche/donnees/administratives .
Chung KC, et al. A cost-utility analysis of amputation versus salvage for Gustilo type IIIB and IIIC open tibial fractures. Plast Reconstr Surg. 2009;124(6):1965–73.
pubmed: 19952652
pmcid: 2788746
doi: 10.1097/PRS.0b013e3181bcf156
Matza LS, et al. Health state utilities associated with post-surgical Staphylococcus aureus infections. Eur J Health Econ. 2019;20(6):819–27.
pubmed: 30887157
pmcid: 6652168
doi: 10.1007/s10198-019-01036-3
Lee BY, et al. Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis. Infect Control Hosp Epidemiol. 2010;31(6):598–606.
pubmed: 20402588
pmcid: 3385994
doi: 10.1086/652524
Sertkaya A, et al. Analytical Framework for Examining the Value of Antibacterial Products. 2014 [cited 2023 October 9, 2023]; Available from: https://aspe.hhs.gov/sites/default/files/migrated_legacy_files//44241/rpt_antibacterials.pdf .
Janjua NZ, et al. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. Int J Drug Policy. 2018;55:31–9.
pubmed: 29482150
doi: 10.1016/j.drugpo.2018.02.001
Statistics Canada. Table 18-10-0005-01 Consumer Price Index, annual average, not seasonally adjusted. 2023 [cited 2023 October 10, 2023]; Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1810000501 .
Canadian Agency for Drugs and Technologies in Health, CADTH methods and guidelines: guidelines for the economic evaluation of health technologies: Canada. 2017, Ottawa, Ontario: Canadian Agency for Drugs and Technologies in Health.
Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989;84(408):1065–73.
doi: 10.1080/01621459.1989.10478873
Therneau TM, Grambsch PM. Multiple events per subject. In: Modeling survival data: extending the Cox Model. Springer; 2000. p. 169–229.
doi: 10.1007/978-1-4757-3294-8_8
Amorim LD, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol. 2015;44(1):324–33.
pubmed: 25501468
doi: 10.1093/ije/dyu222
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
doi: 10.1080/01621459.1999.10474144
Optima Decision Science. Model-based cost-effectiveness and impact assessment of needle-syringe programs in Ontario, Canada from 2006–2015. 2017 [cited 2023 October 16, 2023]; Available from: http://optimamodel.com/pubs/Ontario%20NSP%20evaluation%20report.pdf .
Kerr T, et al. Safer injection facility use and syringe sharing in injection drug users. Lancet. 2005;366(9482):316–8.
pubmed: 16039335
doi: 10.1016/S0140-6736(05)66475-6
Gouvernement du Québec. Distribution of new injection equipment. 2019 [cited 2023 November 30, 2023]; Available from: https://www.quebec.ca/en/health/advice-and-prevention/alcohol-drugs-gambling/distribution-of-new-injection-equipment .
A week after opening, Montreal's safe injections sites report success, in CBC News. 2017.
Yeung MEM, et al. Opioid-related emergency department visits and deaths after a harm-reduction intervention: a retrospective observational cohort time series analysis. CMAJ Open. 2023;11(3):E537–45.
pubmed: 37339791
pmcid: 10287102
doi: 10.9778/cmajo.20220104
Treloar C, et al. Trust and people who inject drugs: the perspectives of clients and staff of Needle Syringe Programs. Int J Drug Policy. 2016;27:138–45.
pubmed: 26394538
doi: 10.1016/j.drugpo.2015.08.018
Ti L, et al. Factors associated with leaving hospital against medical advice among people who use illicit drugs in Vancouver, Canada. PLoS ONE. 2015;10(10):e0141594.
pubmed: 26509447
pmcid: 4624845
doi: 10.1371/journal.pone.0141594
McNeil R, et al. Hospitals as a “risk environment”: an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Soc Sci Med. 2014;105:59–66.
pubmed: 24508718
pmcid: 3951660
doi: 10.1016/j.socscimed.2014.01.010
Jafari S, et al. A community care model of intravenous antibiotic therapy for injection drug users with deep tissue infection for “Reduce Leaving Against Medical Advice.” Int J Ment Health Addict. 2015;13(1):49–58.
pubmed: 25685126
doi: 10.1007/s11469-014-9511-4
Laniece Delaunay C, et al. Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): a Modeling Study. Int J Drug Policy. 2023;116:104026.
pubmed: 37075626
pmcid: 10080278
doi: 10.1016/j.drugpo.2023.104026
Ti L, Ti L. Leaving the hospital against medical advice among people who use illicit drugs: a systematic review. Am J Public Health. 2015;105(12):e53–9.
pubmed: 26469651
pmcid: 4638247
doi: 10.2105/AJPH.2015.302885
Hope V, et al. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis. 2008;8:120.
pubmed: 18801177
pmcid: 2600824
doi: 10.1186/1471-2334-8-120
Nosyk B, et al. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study. Lancet HIV. 2015;2(9):e393-400.
pubmed: 26423553
pmcid: 4610179
doi: 10.1016/S2352-3018(15)00127-7